SOUTH PLAINFIELD, N.J., Aug. 2 /PRNewswire/ -- PTC Therapeutics, Inc.
(PTC), a biopharmaceutical company focused on the discovery, development
and commercialization of small-molecule drugs targeting
post-transcriptional control mechanisms, today announced that Theresa
Natalicchio has been appointed as Senior Vice President of Marketing and
Sales. In this role, she will be responsible for all commercialization
aspects of PTC's programs.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )
"We are excited to welcome Theresa to our management team," said Stuart
Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. "As we begin
commercialization planning for our products, we look forward to leveraging
Theresa's extensive experience in the creation of successful product launch
and marketing campaigns."
"PTC's drug discovery platform has the potential to address a broad
range of genetic disorders, as well as many cancers and infectious
diseases. I have been impressed with the company's unique and innovative
scientific focus and look forward to working with the PTC team to deliver
these potential breakthrough treatments to patients who urgently need
them," commented Ms. Natalicchio.
Ms. Natalicchio comes to PTC with 25 years of product marketing
experience at Pfizer. Inc. where she most recently held the position of
Vice President of the Marketing Centers of Excellence overseeing consumer
strategy, public relations, e-marketing, media, agency management,
multicultural marketing and relationship marketing for Pfizer's portfolio
of US pharmaceutical products. Ms. Natalicchio began her career as a Market
Research Analyst, advancing quickly into roles of increasing responsibility
where she was primarily responsible for launch of blockbuster products such
as Procardia XL(R), Zithromax(R), Zyrtec(R), Viagra(R) and Lyrica(R). Her
previous roles have included U.S. and worldwide marketing, leading
businesses focused on multiple therapeutic areas including arthritis,
anti-infective, urology and women's health.
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery,
development and commercialization of orally administered, proprietary,
small-molecule drugs that target post-transcriptional control processes.
Post- transcriptional control processes regulate the rate and timing of
protein production and are of central importance to proper cellular
function. PTC's internally-discovered pipeline addresses multiple
therapeutic areas, including genetic disorders, oncology and infectious
diseases. In addition, PTC has developed proprietary technologies and
extensive knowledge of post- transcriptional control processes that it
applies in its drug discovery and development activities, including the
Gene Expression Modulation by Small- molecules (GEMS) technology platform,
which has been the basis for collaborations with leading pharmaceutical and
biotechnology companies such as Pfizer, CV Therapeutics and
Schering-Plough. For more information, visit the company's website,
http://www.ptcbio.com.
SOURCE PTC Therapeutics, Inc.
 back to top
Related links:
http://www.ptcbio.com/
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO
CONTACT:
Jane Baj of PTC Therapeutics, Inc.,
+1-908-222-7000 x167, jbaj@ptcbio.com; or Sheryl Seapy of Pure
Communications for PTC Therapeutics, Inc., +1-949-608-0841,
sheryl@purecommunicationsinc.com
|
